The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

Saleh Rachidi, Ehab Saad Aldin, Charles Greenberg, Barton Sachs, Michael B Streiff, Amer M. Zeidan

Research output: Contribution to journalArticle

Abstract

Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondaparinux and warfarin are the agents commonly used for thromboprophylaxis. The well-recognized limitations of warfarin and the inconvenience and discomfort associated with the subcutaneous administration of low molecular weight heparin and fondaparinux inspired intense investigation to develop novel oral anticoagulants (NOACs) with more predictable pharmacokinetics, fewer drug interactions and no need for regular laboratory monitoring. Three NOACs have been demonstrated to be effective for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA) in large randomized controlled trials. Here we review the pharmacology of rivaroxaban, dabigatran, and apixaban, summarize the major clinical trials of these agents in thromboprophylaxis after THA and TKA, and discuss the clinical factors to be considered by providers when selecting a NOAC for their patients.

Original languageEnglish (US)
Pages (from-to)677-695
Number of pages19
JournalExpert Review of Hematology
Volume6
Issue number6
DOIs
StatePublished - 2013

Fingerprint

Anticoagulants
Orthopedics
Knee Replacement Arthroplasties
Low Molecular Weight Heparin
Venous Thromboembolism
Warfarin
Arthroplasty
Hip
Drug Interactions
Randomized Controlled Trials
Pharmacokinetics
Clinical Trials
Pharmacology
Morbidity
Mortality
Incidence
fondaparinux
apixaban
Rivaroxaban
Dabigatran

Keywords

  • Anticoagulants
  • Apixaban
  • Arthroplasty
  • Dabigatran
  • Hip
  • Knee
  • Orthopedic
  • Prophylaxis
  • Replacement
  • Rivaroxaban
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. / Rachidi, Saleh; Aldin, Ehab Saad; Greenberg, Charles; Sachs, Barton; Streiff, Michael B; Zeidan, Amer M.

In: Expert Review of Hematology, Vol. 6, No. 6, 2013, p. 677-695.

Research output: Contribution to journalArticle

Rachidi, Saleh ; Aldin, Ehab Saad ; Greenberg, Charles ; Sachs, Barton ; Streiff, Michael B ; Zeidan, Amer M. / The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. In: Expert Review of Hematology. 2013 ; Vol. 6, No. 6. pp. 677-695.
@article{dc1faa937c604632af0a14d7878e31ac,
title = "The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery",
abstract = "Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondaparinux and warfarin are the agents commonly used for thromboprophylaxis. The well-recognized limitations of warfarin and the inconvenience and discomfort associated with the subcutaneous administration of low molecular weight heparin and fondaparinux inspired intense investigation to develop novel oral anticoagulants (NOACs) with more predictable pharmacokinetics, fewer drug interactions and no need for regular laboratory monitoring. Three NOACs have been demonstrated to be effective for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA) in large randomized controlled trials. Here we review the pharmacology of rivaroxaban, dabigatran, and apixaban, summarize the major clinical trials of these agents in thromboprophylaxis after THA and TKA, and discuss the clinical factors to be considered by providers when selecting a NOAC for their patients.",
keywords = "Anticoagulants, Apixaban, Arthroplasty, Dabigatran, Hip, Knee, Orthopedic, Prophylaxis, Replacement, Rivaroxaban, Venous thromboembolism",
author = "Saleh Rachidi and Aldin, {Ehab Saad} and Charles Greenberg and Barton Sachs and Streiff, {Michael B} and Zeidan, {Amer M.}",
year = "2013",
doi = "10.1586/17474086.2013.853430",
language = "English (US)",
volume = "6",
pages = "677--695",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

AU - Rachidi, Saleh

AU - Aldin, Ehab Saad

AU - Greenberg, Charles

AU - Sachs, Barton

AU - Streiff, Michael B

AU - Zeidan, Amer M.

PY - 2013

Y1 - 2013

N2 - Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondaparinux and warfarin are the agents commonly used for thromboprophylaxis. The well-recognized limitations of warfarin and the inconvenience and discomfort associated with the subcutaneous administration of low molecular weight heparin and fondaparinux inspired intense investigation to develop novel oral anticoagulants (NOACs) with more predictable pharmacokinetics, fewer drug interactions and no need for regular laboratory monitoring. Three NOACs have been demonstrated to be effective for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA) in large randomized controlled trials. Here we review the pharmacology of rivaroxaban, dabigatran, and apixaban, summarize the major clinical trials of these agents in thromboprophylaxis after THA and TKA, and discuss the clinical factors to be considered by providers when selecting a NOAC for their patients.

AB - Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondaparinux and warfarin are the agents commonly used for thromboprophylaxis. The well-recognized limitations of warfarin and the inconvenience and discomfort associated with the subcutaneous administration of low molecular weight heparin and fondaparinux inspired intense investigation to develop novel oral anticoagulants (NOACs) with more predictable pharmacokinetics, fewer drug interactions and no need for regular laboratory monitoring. Three NOACs have been demonstrated to be effective for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA) in large randomized controlled trials. Here we review the pharmacology of rivaroxaban, dabigatran, and apixaban, summarize the major clinical trials of these agents in thromboprophylaxis after THA and TKA, and discuss the clinical factors to be considered by providers when selecting a NOAC for their patients.

KW - Anticoagulants

KW - Apixaban

KW - Arthroplasty

KW - Dabigatran

KW - Hip

KW - Knee

KW - Orthopedic

KW - Prophylaxis

KW - Replacement

KW - Rivaroxaban

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84887855803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887855803&partnerID=8YFLogxK

U2 - 10.1586/17474086.2013.853430

DO - 10.1586/17474086.2013.853430

M3 - Article

VL - 6

SP - 677

EP - 695

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 6

ER -